| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.2 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.04 | 0.2 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.05 | 0.2 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | -0.093 | 0.2 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | VER-155008 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.07 | 0.2 |